Shukra Pharmaceuticals Limited (SHUKRAPHAR) Share Price

BSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE551C01044

₹51.96-0.04 (-0.08%)

Key metrics

Market Cap
₹2,290 Cr
P/E Ratio
66.62
EPS
0.78
Book Value
2.05
P/B Ratio
25.35
ROE
24.55%
ROCE
26.66%
Debt / Equity
0.06
Net Margin
38.88%
Revenue Growth
74.08%
Profit Growth
130.37%
Dividend Yield
0.02%
52W High
₹65.26
52W Low
₹26.18
Market Cap Band
small cap
Face Value

Ratios computed from the annual results period ending 2026-03-31.

About Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals Limited manufactures and markets pharmaceutical products in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin and cephalosporin. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited in August 2016. Shukra Pharmaceuticals Limited was incorporated in 1993 and is based in Ahmedabad, India.

Headquarters
Ahmedabad, India
Promoter Holding
89.32%

The full Shukra Pharmaceuticals Limited analysis

Create a free account to open the complete SHUKRAPHAR deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.

  • 10-year financialsIncome statement, balance sheet and cash flow, year by year.
  • Valuation & fair valueFair-value estimates, quality scores and a value grade.
  • Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
  • Shareholding historyPromoter, FII, DII and public holdings across every quarter.
  • Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
  • Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.